Navigation Links
Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
Date:9/20/2011

SAN DIEGO, Sept. 20, 2011 /PRNewswire/ -- Civic leaders today joined senior management from Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and BioMed Realty Trust, Inc. (NYSE: BMR) to celebrate the completion of a new 176,000 square foot build-to-suit corporate and research facility on Gazelle Court in the Carlsbad Oaks North Business Park in Carlsbad. Among the featured speakers at the ceremony were Stanley T. Crooke, M.D., Ph.D., Chairman and Chief Executive Officer, and B. Lynne Parshall, Chief Operating Officer and Chief Financial Officer, of Isis; Matt Hall, Mayor of the City of Carlsbad; and Alan D. Gold, Chairman and Chief Executive Officer of BioMed.

The state-of-the-art complex consolidates the majority of Isis' operations into a single facility, which will foster the company's collaborative and unique approach to drug discovery and development. Isis and BioMed broke ground on the new building in June 2010.

"Our new facility combines functional and efficient design features to meet our current and future needs and foster our collaborative approach to drug discovery and development," said Dr. Crooke.  "Completed ahead of schedule and below budget by BioMed, our real estate partner since 2005, our new corporate home provides the ideal environment for us to continue to innovate and create the medicines of tomorrow.  We are very pleased to share this special occasion for all of us at Isis with Mayor Hall and the other civic leaders from the City of Carlsbad, representatives from the San Diego life science community, our construction partners and, of course, Isis employees and their families."

"Isis Pharmaceuticals is a major player in the life sciences industry and the regional economy.  We couldn't be more pleased that Isis chose Carlsbad as the location for this st
'/>"/>

SOURCE BioMed Realty Trust, Inc.; Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
(Date:9/23/2014)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... address unmet medical needs in the areas of ... has appointed Rasappa Arumugham , PhD, as ... has over 25 years of diverse experience in ... of formulation research, analytical method development, quality control ...
(Date:9/23/2014)... Sept. 23, 2014  As physicians seek information ... communication channels to learn about new therapies or ... from a new report by global sales and ... that communicating via a customized mix of digital ... best opportunity to engage with physicians. And, productive ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 3Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock ... Auditorium Seattle concert posters. The Doors were a smash hit ... year. The Seattle Eagles Auditorium concert was held on July ... to Eagles Auditorium in November the same year. The artist ... comes in three colors. The poster is a split fountain ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... national report showing the benefits of preventing a ... Medicaid services was released today by the American ... Congress Must Save the Medicaid Primary Care Pay ... Access to Life-Saving Primary Care Will Expire," explains ... access to internists and pediatricians (and their related ...
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... for allergic rhinitis (AR) is highly fragmented, ... different SIT formulations available, under different regulatory ... between markets. Europe has the most developed ... (SLIT), and allergen immunotherapy tablets (AITs) all ...
(Date:9/23/2014)... York, New York (PRWEB) September 23, 2014 ... forward in courts around the country, Bernstein Liebhard LLP ... Court, Middle District of Florida on September 19th, the ... from a case filed in that jurisdiction on behalf ... growth) and other complications due to his use of ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... The makers of the WaveSense(TM) line of blood ... commitment to providing low cost, high accuracy, and high ... diabetes. The WaveSense Presto(TM) BGM can be found at ... strips (50 ct) are often as low as $22.88, ...
... The Hazelden Foundation, one of the world,s largest and ... centers, announced today that the Rev. Michael J. O,Connell ... of Trustees. O,Connell succeeds Norbert J. Conzemius, who served ... http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ) , , "The Rev. O,Connell ...
... -- GHX honored 12 healthcare provider and supplier ... chain performance. The awards were presented on Wednesday, June 3, ... Annual GHX Supply Chain Summit - the largest forum in ... of the healthcare supply chain. , , The theme ...
... in Under 4 years , , PLEASANTON, Calif., June ... Photopneumatic system in the United States. The installation of the ... base to approximately 1800 systems worldwide. The company has direct ... of distributors in over 20 countries in Asia, Europe and ...
... , , ... ANDS ) announced that it has entered into ... in gross proceeds in a "registered direct" offering through the ... estimates that net proceeds from the offering will be approximately ...
... 4 As the administration moves forward with health care ... research released this week by the Deloitte Center for Health ... Diego highlights how comparative effectiveness and consumerism will challenge the ... , During a time when the majority of U.S. consumers ...
Cached Medicine News:Health News:WaveSense Reduces Diabetes Testing Cost by 50% 2Health News:The Rev. Michael J. O'Connell Assumes Chairmanship of Hazelden Foundation Board of Trustees 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3Health News:Aesthera Announces Installation of 1000th Photopneumatic System in US 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 2Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 4Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 5
... HIV-1 Antibody Test (Reveal Test) is MedMiras ... antibodies in human serum or plasma against ... in response to HIV infection. The Reveal ... membrane technology, and is comprised of a ...
... The OraQuick ADVANCE Rapid ... a single-use, qualitative immunoassay ... Human Immunodeficiency Virus Type ... 2 (HIV-2) in oral ...
... The advanced performance benefits ... been applied to the ... Implants) Upper Extremity Plates. ... combine to provide a ...
... of TiMAX material have been applied to a ... and an ultra-low profile combine to provide a ... extremity. , ,This complete set of periarticular plates ... , Fibula Composite Plate , Spider ...
Medicine Products: